
Gaithersburg-based Emergent BioSolutions has made the decision to cut 400 jobs and scale back operations at some its facilities, instead focusing on core products such as overdose reversal nasal spray Narcan and anthrax vaccines. The company is also eliminating its chief operating officer (COO) position. According to WTOP, “the job cuts are at Emergent’s Bayview facility in Baltimore, at its drug production facility in Rockville, as well as another facility in Canton, Massachusetts.”
In March, the FDA granted the over-the-counter approval of Narcan to Emergent BioSolutions. It became the first naloxone product approved for use without a prescription. “Emergent’s business pivot is expected to result in yearly savings of more than $100 million, the company explained. The moves will cost Emergent around $20 million—costs it expects to incur in the third quarter of 2023.” according to FiercePharma.
Featured photo courtesy of Google Maps.